



## Krystal Biotech Appoints Jennifer Chien as Chief Commercial Officer

January 21, 2020

PITTSBURGH, Jan. 21, 2020 (GLOBE NEWSWIRE) -- [Krystal Biotech](#), Inc. (Nasdaq:KRY5), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer Chien to the newly created position of chief commercial officer, effective January 20, 2020. Ms. Chien has more than 20 years of commercial leadership experience in the biopharmaceutical industry, most recently having served as vice president, head of genetic diseases at Sanofi Genzyme.

"We are excited to welcome Jennifer to Krystal Biotech as we look forward to launching KB103, for the treatment of dystrophic epidermolysis bullosa, in 2021," said Krish S. Krishnan, chairman and chief executive officer of Krystal Biotech. "Jennifer's leadership and broad experience launching new medicines will be critical as we continue to build the commercial capabilities needed to become a sustainable, fully-integrated, multi-product gene therapy company."

Jennifer Chien, chief commercial officer of Krystal Biotech commented, "I am thrilled to join Krystal Biotech at such a pivotal time. My decision to join was based off Krystal's promising technology platform, its rare disease pipeline and the people at Krystal who share a commitment to developing breakthrough medicines to patients with debilitating diseases. I look forward to working with the team to build a leading commercial organization and advance treatment options for the benefit of patients."

As vice president, head of genetic diseases at Sanofi Genzyme, Ms. Chien was responsible for the U.S. commercial strategy and implementation for seven brands and preparation for upcoming launches within rare diseases. During her tenure at Sanofi Genzyme, she also held global leadership roles as VP, head of global nephrological diseases, senior director global marketing Fabry disease, senior director global market access and international marketing for the cardiovascular business, in addition to leading business development efforts within various therapeutic areas. Ms. Chien holds a B.S. degree from Massachusetts Institute of Technology and a MPH degree from Harvard University.

### **About Krystal Biotech**

Krystal Biotech, Inc. (NASDAQ:KRY5) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from rare diseases. For more information, please visit <http://www.krystalbio.com>.

### **Forward-Looking Statements**

This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding the potential launch of KB103 to treat the underlying causes of dystrophic epidermolysis bullosa, company's promising technology platform and the potential for rapid development of the company's clinical programs. You can identify forward-looking statements because they contain words such as "believes" and "expects." Forward-looking statements are based on Krystal's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Krystal's filings with the Securities and Exchange Commission, including its registration statement on Form S-1 and Form 10-K, as amended from time to time, under the caption "Risk Factors."

### **INVESTOR CONTACT**

Ashley R. Robinson  
LifeSci Advisors  
[arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)

### **MEDIA CONTACT**

Darren Opland, PhD  
LifeSci Communications  
[darren@lifescicomms.com](mailto:darren@lifescicomms.com)

Source: Krystal Biotech, Inc.



Source: Krystal Biotech, Inc.